botensilimab,balstilimab
agenus
botensilimab, an fc-enhanced igg1 #ctla4 antibody, brings new hope to patients with 2l+ mss-crc. #esmogi. unprecedented activity. 24% orr, 73% dcr (n=41). durable responses across ras mutations. enriched responses in patients without liver mets (n=24): 42% orr and 96% dcr.
Scientist